deltatrials
Completed NA INTERVENTIONAL 2-arm NCT02962297

Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis

VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China

Sponsor: R&G Pharma Studies Co.,Ltd.

Conditions NASH (Non-Alcoholic Steatohepatitis)
Interventions Placebo Vitamin E softgel
Updated 17 times since 2017 Last updated: Mar 30, 2023 Started: Dec 31, 2016 Primary completion: Nov 9, 2020 Completion: Dec 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on NASH (Non-Alcoholic Steatohepatitis), this trial is completed. The trial is conducted by R&G Pharma Studies Co.,Ltd. and has accumulated 17 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Jan 2018 · 5 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Dec 2020 · 22 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~May 2023 · 14 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Sep 2024 — Sep 2025 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. May 2023 — Jul 2024 [monthly]

    Completed NA

  5. Mar 2022 — May 2023 [monthly]

    Completed NA

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting NA

  2. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting NA

  3. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting NA

  4. Feb 2019 — Dec 2020 [monthly]

    Active Not Recruiting NA

    Status: Enrolling By Invitation → Active Not Recruiting

  5. Aug 2018 — Feb 2019 [monthly]

    Enrolling By Invitation NA

    Status: Recruiting → Enrolling By Invitation

  6. Jun 2018 — Aug 2018 [monthly]

    Recruiting NA

  7. Apr 2018 — Jun 2018 [monthly]

    Recruiting NA

  8. Jan 2018 — Apr 2018 [monthly]

    Recruiting NA

  9. Aug 2017 — Jan 2018 [monthly]

    Recruiting NA

  10. Jul 2017 — Aug 2017 [monthly]

    Recruiting NA

  11. Feb 2017 — Jul 2017 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  12. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • R&G Pharma Studies Co.,Ltd.
  • The Affiliated Hospital of Hangzhou Normal University
  • Zhejiang Medicine Co., Ltd.
Data source: Zhejiang Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijin, China , Beijing, China , Chengdu, China , Guangdong, China , Guangzhou, China , Hangzhou, China , Luzhou, China , Nanjing, China , Shenyang, China , Tianjin, China and 3 more locations